Orgazmo 100-Gram Bag: Technical Overview, History, & Health Risks
Orgazmo 100-Gram Bag refers to a bulk-format product from a notorious brand of synthetic cannabinoid-laced “herbal incense” that was distributed by federally prosecuted trafficking networks. Despite being labeled “not for human consumption,” these products were manufactured and sold explicitly for their psychoactive effects. Orgazmo-branded products were specifically identified in U.S. Department of Justice prosecutions involving the manufacture and distribution of synthetic cannabinoids under the guise of legitimate incense companies.
Brand History and Federal Prosecution
Orgazmo was one of several brand names (alongside Bizarro, Posh, Sonic Zero, Headhunter, and Neutronium) manufactured by Zencense Incense Works LLC, ZenBio LLC, and Biozen LLC. Court records show these operations were based in Millbrae and Stockton, California, and distributed products to smoke shops across the United States.
Federal prosecutors established that:
-
The drugs were deliberately misbranded and marketed as “potpourri” or “herbal incense” claimed to be “not for human consumption,” but the operators fully intended them to be used as narcotics.
-
The operation generated over $32 million in illicit income in five months and involved at least 11 tons of smokable synthetic cannabinoids.
-
Products contained synthetic cannabinoids including AM-2201, JWH-018, and XLR11—compounds now classified as Schedule I drugs under the Controlled Substances Act.
In 2016, the New York Attorney General’s office also filed suit against an online distributor (LegalHerbalBud) selling Orgazmo brand products at $30–$50 per unit, describing the drugs as causing “psychosis, asphyxiation, and death”.
Health Risks and Emergency Response
Orgazmo products, like all synthetic cannabinoid blends, carry severe and unpredictable health risks. The New York State Department of Health and the MSD Manual provide authoritative clinical guidance on the effects of K2/Spice products. You can Orgazmo 100-GRAM Bag online from k2 sheet shop.
Acute clinical effects include:
| System | Documented Effects |
|---|---|
| Neurological | Seizures, stroke, agitation, confusion, loss of consciousness, altered mental status |
| Psychiatric | Hallucinations, delusions, psychosis (may be irreversible), violent behavior, suicidal thoughts |
| Cardiovascular | Tachycardia, hypertension, chest pain, heart attack |
| Other | Severe vomiting, rhabdomyolysis (muscle breakdown), kidney failure, death |
Why the danger is amplified in bulk products: The crude spraying process used to apply synthetic cannabinoids onto plant material can create “hot pockets” —areas within a single product where the chemical is highly concentrated. This means even within one 100-gram bag, potency can vary dramatically, making it impossible for users to control their dose and increasing the risk of inadvertent toxic overdose.
Detection limitations: Standard urine drug tests for cannabis do not detect synthetic cannabinoids like those in Orgazmo products. Specialized mass spectrometry testing is required but not routinely available.
Authoritative Sources for Further Information
For accurate, evidence-based information on synthetic cannabinoids and their risks, consult these authoritative resources:
| Organization | Resource |
|---|---|
| U.S. Drug Enforcement Administration (DEA) | Information on controlled substance scheduling and enforcement actions |
| New York State Department of Health | Clinical guidance for healthcare providers on K2 recognition and treatment |
| European Union Drugs Agency (EUDA) | Market analysis and health risk assessments for synthetic cannabinoids in Europe |
| MSD Manual (Professional Edition) | Clinical diagnosis and treatment protocols for synthetic cannabinoid intoxication |
Emergency Response
If someone shows signs of severe intoxication from Orgazmo or any synthetic cannabinoid product—agitation, seizures, unresponsiveness, difficulty breathing, or extreme confusion—call emergency services immediately (911 in the US, 999 in the UK). Treatment is primarily supportive, including IV sedation with benzodiazepines and monitoring for rhabdomyolysis and organ damage.
If you are struggling with substance use, the SAMHSA National Helpline is available 24/7 at 1-800-662-4357, or visit findtreatment.gov.
Reviews
There are no reviews yet.